Last reviewed · How we verify
Induction of ovulation in unexplained infertility — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Femara | letrozole | Novartis AG | Aromatase Inhibitor [EPC] | aromatase enzyme | 1997-07-25 | |
| Femara | Femara | M.D. Anderson Cancer Center | Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- M.D. Anderson Cancer Center · 1 drug in Induction of ovulation in unexplained infertility
- Novartis AG · 1 drug in Induction of ovulation in unexplained infertility
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Induction of ovulation in unexplained infertility:
- Induction of ovulation in unexplained infertility treatment updates — RSS
- Induction of ovulation in unexplained infertility treatment updates — Atom
- Induction of ovulation in unexplained infertility treatment updates — JSON
Cite this brief
Drug Landscape (2026). Induction of ovulation in unexplained infertility — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/induction-of-ovulation-in-unexplained-infertility. Accessed 2026-06-10.
Related
- Induction of ovulation in unexplained infertility full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing